Croda has underlined its confidence in the future growth of its innovative drug delivery systems into the human body beyond the huge uptick delivered by Covid wins.
Opportunities in the pharmaceutical market have been highlighted to investors when it comes to the administration of complex biologic drugs.
The East Yorkshire-headquartered FTSE-listed firm is expanding production capacity at home and abroad, with support from the UK and US governments, as revealed earlier this year.
